IntroductionNevus lipomatosus cutaneous superficialis (NLCS) is a rare benign hamartomatous skin tumor characterized by dermal deposition of mature adipose tissue. It’s classified in two types: the classical form with multiple soft, pedunculated, cerebriform papules and nodules that coalesce into plaques, and the solitary form that consists of a solitary papule or nodule. In this study, eight cases of NLCS are reported.MethodsThe study was a retrospective case series including all patients with histopathologically documented NLCS who attended the Dermatology Department of Charles Nicolle hospital between January 1997 and December 2010. The objective of our study was to determine the epidemioclinical characteristics, the histopathologic features, and the treatment of this hamartoma. Patients included three males and five females aged between 7 and 41 years.ResultsIn four cases hamartoma was present since childhood, and in the other four cases it appeared in the third and fourth decades. Classical form was noted in seven cases and the solitary form in one case. Lesions involved limbs in four patients and trunk in four patients. Seven patients underwent surgical excision, and for one case no treatment was proposed.ConclusionThe multiple or classical form is largely predominant in our study. Habitually, NLCS has an asymptomatic course. Treatment is usually not necessary unless for cosmetic reasons; surgical excision is curative and recurrence after is rare.
BackgroundLupoid cutaneous leishmaniasis (CL) is a rare form of CL having a striking resemblance to other granulomatous cutaneous conditions of infectious or inflammatory origin. The authors present a patient with a facial lupoid CL and discuss the diagnostic tools of this parasitological infection, the main differential diagnosis, and treatment.Case reportA 54-year-old Tunisian woman, with no past medical history of lupus erythematosus or infectious disease, presented with a 3-month history of a slowly enlarging erythematous and infiltrated plaque, extending over the nose, the right cheek, and the internal aspect of the right lower eyelid. Microscopic examination of a parasitological smear showed numerous leishmania in their amastigote form, inside monocytes, confirming the diagnosis of CL. Clinical aspect was in favor of lupoid CL. The patient was cured by fluconazole 200 mg/day for 6 weeks after pancreatic intolerance with intramuscular meglumine antimoniate (60 mg/kg/day for 7 days), and no response to doxycycline (200 mg/day for 6 weeks).DiscussionLupoid CL is easily suspected in countries in which there is an endemic of leishmaniasis. In countries where there isn’t an endemic, although rarely observed, this diagnosis should also be kept in mind in front of an infiltrated facial lesion of a tuberculoid aspect on histology, especially when there is a positive travel history to an area in which there is an endemic.
BackgroundErosive lichen planus (LP) of the soles is a rare variant of LP, characterized by chronic, painful, and disabling plantar ulcerations. Herein, we report a case with complete healing following treatment with systemic steroids.Case reportA 38-year-old woman was referred with painful and disabling erosive bilateral plantar LP, which she had experienced for 6 weeks. A 1 mg/kg/day, oral prednisone therapy led to rapid improvement and complete healing within 3 weeks, with a sustained result under a low dose maintenance therapy.DiscussionUlcerative plantar LP is significantly known to be unresponsive to several topical and systemic therapies. Surgical excision and grafting is the treatment of choice. Systemic steroids are reported to have inefficient or partial results; both on cutaneous healing and on maintenance of the result. Our patient achieved complete cicatrisation with a sustained result of 3 months under a low dose of prednisone (5 mg/day).
Rosacea is a chronic inflammatory skin disease, affecting commonly patients with fair skin. It is characterized by persistent facial erythema that could cause cosmetic disfigurement, psychosocial burden and significant impact on patients' quality of life. 1 The updated classification of the National Rosacea Society defines diagnostic phenotypes, with the fixed centrofacial erythema being a characteristic clinical phenotype. 1 Treatment of erythematotelangiectatic rosacea (ETR) is challenging. 2 Current treatment options include energy-based devices (such as laser, intense pulsed light, and electrocoagulation) 3 and brimonidine gel. The latter was recently introduced. Its effect is transient with frequent treatment escape within 24 h. 2 The therapeutic benefit of repeated botulinum toxin mesotherapy sessions in ETR was also reported, probably through acetylcholine blocking effects. 4 Nevertheless, this therapeutic modality is considered so costly.Tranexamic acid (TXA) is an antifibrinolytic drug that reduces the risk of excessive bleeding in menorrhagia, hemophilia, as well as major surgery. TXA has been used for the treatment of several skin diseases such as angioedema and melasma. 5,6 To date, only few studies described the use of TXA in the treatment of rosacea, topically or by microneedling, with encouraging results. 6,7,8,9 None of these studies evaluated intralesional microinjection of TXA for the
BackgroundThe bullous variant of Darier’s disease (DD) is a rare type characterized by histological and clinical overlap with Hailey-Hailey disease (HDD).Case reportsThe following case report describes two cases of familial DD; a 51-year-old woman who presented with erythematous plaques, covered by small blisters in axillary and inguinal areas, and the first patient’s daughter, who presented with keratotic papules localized on the axillary and inframammary folds.ConclusionThese two cases are original by the predominant flexural distribution, and by a bullous form in the first case, clinically and histologically mimicking HHD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.